Clinical Trials Logo

Clinical Trial Summary

This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06387420
Study type Interventional
Source Akeso
Contact Jie Yang, MD
Phone +86(0760)89873999
Email jie.yang@akdsobio.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date April 29, 2024
Completion date April 2027

See also
  Status Clinical Trial Phase
Recruiting NCT04429191 - JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation Phase 1